SHARON SWEETEN: Open Payments
NPI 1841630969 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,769 in 49 payments from 19 companies in 2025. Trend: 2023 $1,767 · 2024 $1,127 · 2025 $1,769
Food & beverage: $1,769
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 10 | $193 |
| Actelion Pharmaceuticals US, Inc. | 3 | $181 |
| Amgen Inc. | 5 | $180 |
| Novo Nordisk Inc | 4 | $175 |
| SCPHARMACEUTICALS INC. | 3 | $149 |
| ABIOMED | 1 | $126 |
| Corcept Therapeutics | 1 | $123 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $96 |
| Merck Sharp & Dohme LLC | 5 | $88 |
Products named: LEQVIO, REPATHA, FUROSCIX, Ozempic, Korlym, AMVUTTRA, UPTRAVI, JOURNAVX.
Industry payments across TX — which companies pay providers there.
